Caraco Pharmaceutical Laboratories Ltd. Announces FDA Approval To Market Generic Ambien(R)

view article

Published at: www.medicalnewstoday.com

Generics hit the mark and save you money

May 1, 2007

Analysis by: GLG Expert Contributor

Zolpidem is very widely used and the generic should have a substantial market.

Generic yes -safe?

April 30, 2007

Analysis by: GLG Expert Contributor

It is interesting that the FDA has put out warnings on the safety of sleeping meds. Yet it approves a generic form of the most popular medication. Will getting a drug cheaper make is safer?

David RosenbergChief of Psychiatry and PsychologyCHILDREN'S HOSPITAL OF MICHIGAN

More Generics Needed

April 30, 2007

Urgent need for generic

Proprietary medications often prohibitively expensive

Insurance plans often prefer generic equivalents

Ambien Goes Generic: What will the Market Look Like?

April 25, 2007

Analysis by: GLG Expert Contributor

Caraco Pharmaceutical Laboratories, Ltd., (Amex: CPD) is one among 13 companies approved by the FDA (on April 23) to market the generic version of the drug Ambien (zolpidem tartate) as a short-term treatment for insomnia.

The FDA’s recent request that manucturers of hypnotic drugs strengthen their label to warn against complex, potentially dangerous sleep-related behaviors, has led to speculation that certain hypnotic drugs may be less commonly prescribed.

 

Ambien(R): Caraco Pharmaceutical Laboratories Ltd. to Rise, Sanofi –Aventis to fall a some

April 25, 2007

Analysis by: GLG Expert Contributor

The launch of a generic form of Ambien(R), Zolpidem Tartrate Tablets, can expect a short term rise in Caraco Pharmaceutical Laboratories, Ltd., (Amex: CPD), and a downward slope on the curves for Sanofi-aventis the innovator of Ambien(R)